Researchers seeking to buy CJC-1295 Ipamorelin formulations for laboratory evaluation require analytical-grade, high-purity compounds backed by rigorous lot-specific documentation. PX1 Research supplies USA-manufactured research peptides synthesized in GMP-compliant facilities and verified via reverse-phase HPLC and mass spectrometry. All compounds are strictly designated for in vitro, ex vivo, and animal model research applications.
Researchers seeking to buy CJC-1295 Ipamorelin formulations for laboratory evaluation require analytical-grade, high-purity compounds backed by rigorous lot-specific documentation. PX1 Research supplies USA-manufactured research peptides synthesized in GMP-compliant facilities and verified via reverse-phase HPLC and mass spectrometry. All compounds are strictly designated for in vitro, ex vivo, and animal model research applications.
When evaluating options to buy CJC 1295 Ipamorelin for laboratory research, investigators must source from vendors providing verified purity and lot-specific analytical documentation. PX1 Research supplies USA-manufactured, research-grade CJC-1295 and Ipamorelin with >99% sequence purity, verified by RP-HPLC and ESI-MS. These synthetic secretagogues are strictly intended for in vitro assays and preclinical models assessing somatotrophic axis activation.
Sourcing research peptides requires uncompromising control over batch uniformity, TFA removal, and endotoxin thresholds. Laboratories relying on precise receptor target binding data require research compounds that are free of truncated synthetic artifacts or unreacted reagents. PX1 Research maintains full batch traceability from synthesis through lyophylization and dispatch, operating distribution hubs in California and Arizona to support prompt fulfillment.
CJC-1295 is a synthetic 29-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH, 1-29). It was engineered to substitute specific residue locations to resist enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), an enzyme responsible for rapidly degrading endogenous human GHRH. In biochemical studies, this molecular modification significantly extends the biological half-life of the peptide compared to native GHRH.
In preclinical literature, CJC-1295 is studied as a long-acting growth-hormone-releasing hormone analog that sustains growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research. The compound exists in two primary formulations: CJC-1295 with Drug Affinity Complex (DAC), which bioconjugates to circulating serum albumin to extend half-life to several days, and CJC-1295 No DAC (also referred to as Modified GRF 1-29), which exhibits a shorter half-life that closely mimics physiological physiological pulsatile GHRH release.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a selective growth hormone secretagogue. Unlike older generation peptides in its functional category, Ipamorelin acts as a highly selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), commonly referred to as the ghrelin receptor.
In vitro competitive binding assays demonstrate that Ipamorelin binds GHSR-1a with high affinity without stimulating secondary endocrine pathways. Preclinical models indicate that Ipamorelin does not induce significant elevations in plasma cortisol, adrenocorticotropic hormone (ACTH), prolactin, or aldosterone, even when administered at supra-physiological dosages in animal models. This selectivity makes it a primary tool for isolated GHRH/GHSR co-activation studies.
The co-administration of CJC-1295 and Ipamorelin is a widely utilized methodology in somatotrophic axis research due to complementary receptor targets. CJC-1295 binds to and activates the GHRH receptor (GHRHR) on pituitary somatotropes, initiating intracellular cAMP cascades via adenylate cyclase stimulation. Concurrently, Ipamorelin engages the GHSR-1a receptor, triggering intracellular calcium influx via the phospholipase C (PLC) and inositol trisphosphate (IP3) signaling pathways.
Preclinical studies suggest that simultaneous activation of GHRHR and GHSR-1a yields a synergistic amplification of growth hormone release from anterior pituitary cells. In vitro pituitarism assays reveal that combining a GHRH agonist with a GHSR agonist produces a peak secretory response far exceeding the additive total of either compound administered independently. This dual-action pathway allows researchers to examine maximal somatotroph responsiveness while mitigating receptor desensitization.
Animal study models investigating the CJC-1295 and Ipamorelin combination frequently measure serum biomarker kinetics across fixed sampling intervals. Research models demonstrate that co-infusion leads to transient, pronounced pulses of growth hormone, followed by dose-dependent elevations in liver-derived IGF-1 expression. Because IGF-1 serves as a primary mediator of cell proliferation, protein synthesis, and extracellular matrix remodeling, this dual protocol is heavily referenced in preclinical muscle tissue, tendon, and articular cartilage repair research.
Furthermore, in vivo rodent studies indicate that sustained stimulation of the somatotrophic axis via these secretagogues influences cellular metabolic rate, lipid mobilization, and nitrogen retention without causing chronic basally elevated GH elevation when non-DAC formulations are utilized. Detailed comparisons regarding secretagogue signaling pathways are expanded upon in our growth hormone secretagogues guide.
When designing preclinical trials, investigators often contrast CJC-1295 and Ipamorelin with other peptide analogs targeting the somatotrophic axis. For instance, Sermorelin is a shorter-chain GHRH (1-29) fragment that exhibits rapid clearance and lower binding stability compared to CJC-1295. Similarly, Tesamorelin features a hexenoyl moiety attached to the N-terminus of GHRH, optimized specifically for hepatic metabolic and visceral adipose research models.
On the ghrelin receptor agonist side, compounds such as GHRP-6 and GHRP-2 demonstrate potent GH releasing capability but lack the receptor selectivity of Ipamorelin, frequently causing concomitant spikes in prolactin and cortisol during animal trials. Evaluating these operational differences allows researchers to select the precise molecular tool for their laboratory protocols. Researchers can review all related compounds across our comprehensive research peptides catalog.
Reliable experimental outcomes depend entirely on the purity and structural integrity of the research compounds. At PX1 Research, every batch of CJC-1295 and Ipamorelin undergoes independent testing by an accredited ISO 17025 third-party laboratory. We utilize High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity, ensuring that active peptide content meets or exceeds 99.0%.
To verify sequence order and molecular mass, Electrospray Ionization Mass Spectrometry (ESI-MS) analysis is performed on every lot. This ensures the total molecular weight matches theoretical calculation down to fractional Daltons, confirming the complete absence of deletion sequences or incomplete synthesis side-products. A lot-specific Certificate of Analysis (COA) is generated and published for full transparency.
Bacterial endotoxins (lipopolysaccharides) introduce significant confounding variables in cell culture and animal models, potentially triggering immune activation, cytokine release, or cell toxicity. PX1 Research subjects all lyophilized peptide batches to rigorous Chromogenic Recombinant Factor C (rFC) or LAL endotoxin testing to confirm levels remain far below established research thresholds (<0.01 EU/mg).
All synthesis, purification, and lyophilization steps are performed within state-of-the-art, GMP-compliant facilities. By adhering to cleanroom air quality standards and strict sterile filtration protocols prior to freeze-drying, PX1 Research delivers laboratory reagents suitable for sensitive in vitro assays and high-precision analytical research.
Proper handling and storage are critical to maintain the peptide matrix integrity over time. Lyophilized CJC-1295 and Ipamorelin vials should be stored at -20°C upon receipt for long-term stability, protected from light exposure. Prior to opening, vials should be allowed to equilibrate to room temperature to prevent condensation from forming inside the container.
Reconstitution should be conducted using sterile laboratory solvents under a laminar flow hood. Bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline is typically introduced slowly along the glass wall of the vial to minimize shear force degradation. For step-by-step guidance on calculating lab concentrations and solvent selection, consult our technical resource on peptide reconstitution protocols.
PX1 Research supports university laboratories, biotechnology organizations, and contract research organizations (CROs) requiring dependable supplies of high-purity peptides. We maintain substantial inventory buffers at our US facilities to guarantee same-day dispatch for orders placed Monday through Friday prior to cut-off times.
For high-throughput screening projects or large-scale animal studies requiring consistent multi-gram batch allocations, laboratories can access customized bulk fulfillment and dedicated account management through our bulk research accounts portal.
What is the primary operational difference between CJC-1295 and Ipamorelin?
CJC-1295 functions as a growth hormone-releasing hormone (GHRH) receptor agonist, whereas Ipamorelin acts as a selective ghrelin receptor (GHSR-1a) agonist. They target two distinct receptor classes on pituitary somatotropes.
How does PX1 Research verify the purity of CJC-1295 Ipamorelin?
Every lot is analyzed by an independent ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination and Mass Spectrometry (ESI-MS) for molecular weight verification.
Are CJC-1295 and Ipamorelin supplied pre-mixed or in separate vials?
PX1 Research offers both individual high-purity vials ([CJC-1295 No DAC](/product/cjc-1295-no-dac) and [Ipamorelin](/product/ipamorelin)) as well as precise blend formulations, depending on the requirements of your analytical research protocol.
What are the recommended storage conditions for lyophilized research peptides?
Lyophilized vials should be stored at -20°C for long-term stability. Once reconstituted, solutions should be kept refrigerated at 2°C to 8°C and evaluated within short experimental timeframes to prevent hydrolytic degradation.
What endotoxin limits are maintained for PX1 Research compounds?
All peptide batches undergo strict endotoxin testing to confirm levels remain below standard research thresholds, typically <0.01 EU/mg, minimizing non-specific inflammatory signaling in downstream assays.
Why is CJC-1295 No DAC often preferred over CJC-1295 DAC in combination research?
CJC-1295 No DAC features a shorter plasma half-life that allows researchers to model physiological, pulsatile growth hormone release when co-infused alongside Ipamorelin, avoiding the continuous baseline elevation caused by the DAC complex.
Can CJC-1295 Ipamorelin be used in human clinical applications?
No. All products sold by PX1 Research are strictly designated for laboratory in vitro, ex vivo, and preclinical research use only. They are not for human or animal therapeutic, diagnostic, or clinical use.
Where are PX1 Research peptides manufactured and dispatched from?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and dispatched directly from optimized distribution facilities located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.